In a recent study, tanezumab proved safe and effective in the treatment of knee and hip osteoarthritis…
SM04690 Promising for Knee OA
SM04690, an intra-articular injection for knee OA, will soon enter phase 3 trials to assess its effects on pain, joint function and disease…
Hip Exercises May Improve Walking, Pain with Knee Arthritis
(Reuters Health)—Patients with knee osteoarthritis (OA) can add hip-strengthening exercises to their workout to improve the ability to walk and maybe reduce pain, according to a research review. Based on pooled data from eight clinical trials with a total of 340 patients, hip strengthening exercises involving weights or elastic bands would help the most, the…
Does Loss of Skeletal Muscle Mass Increase the Risk of Knee OA?
Obesity is a well-known risk factor for knee osteoarthritis (OA), but data regarding the association of body composition (fat and muscle mass) with the risk of knee OA are lacking. Thus, it is not clear whether the effects of BMI, typically interpreted as effects of obesity, are truly due to excess adiposity rather than to overall loading due to the combined weight of body mass. Misra et al. undertook this study to examine the longitudinal association of body composition categories based on fat and muscle mass with the risk of incident knee OA…
OA Patient-Reported Outcomes Positive for Intra-Articular Injection
In a recent Phase 2 clinical trial, patient-perceived pain and function measures improved with SM04690, an injectable, disease-modifying osteoarthritis treatment currently in development…
Coding Corner Answers: Billing for Joint Injection within a Series
Take the challenge. CPT: 20611-LT, J7325-EJ ICD-10: M17.12, E66.01, Z68.41 Coding/Billing Rationale No evaluation and management (E/M) code was added because there was no significant and/or separate identifiable reason for an E/M service to be billed with this scheduled visit for her series of injections. The joint injection was billed with ultrasound guidance due to…
Coding Corner Question: Billing for Joint Injection within a Series
A 68-year-old female Medicare patient with a diagnosis of primary osteoarthritis of the left knee returns to a practice for her third injection in a series of knee injections. She reports being able to resume her after-dinner walks, which last for 30–40 minutes at least twice weekly. She denies fevers or any rashes. She has…
Is More Better? Weight Loss Analysis in Older Patients with Knee OA
Obesity is a modifiable risk factor for many patients with knee osteoarthritis (OA), and the National Institutes of Health recommend an initial weight loss goal of 10%. But how does losing more weight affect knee OA patients? In a new study, researchers compared the outcomes of knee OA patients who lost more and less than the recommended 10% of their baseline weight, finding significant improvement in health-related quality of life and reduction in pain for patients who lost twice what’s recommended…
Zilretta Promising for Blood Glucose Levels; Plus Filgotinib Promising for RA
A recent study suggests Zilretta, an intra-articular injection for OA knee pain, may lower blood glucose levels in OA patients…
The FDA Denies Approval for Remoxy Extended Release; Plus Knee OA Pain Treatment Moves into Phase 3 Trials
The FDA has not approved extended release Remoxy, a gel capsule formulation of oxycodone, concluding that its potential benefits do not outweigh its risks…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 7
- Next Page »